Systemic corticosteroids for the outpatient treatment of necrobiosis lipoidica in a diabetic patient.

Necrobiosis lipoidica (NL) remains a major therapeutic challenge for the dermatologist and diabetologist. Amongst many treatment modalities attempted, systemic corticosteroids remain controversial, not least because a proportion of NL patients are diabetic, and corticosteroids are likely to destabilize their diabetic control. Close supervision as an inpatient is often required. We report the ambulatory outpatient management of an insulin-dependent diabetic with ulcerated necrobiosis lipoidica complicated by activated protein C resistance.
AuthorsEunice Tan, Vinod Patel, John Berth-Jones
JournalThe Journal of dermatological treatment (J Dermatolog Treat) Vol. 18 Issue 4 Pg. 246-8 ( 2007) ISSN: 0954-6634 [Print] England
PMID17671885 (Publication Type: Journal Article)
Chemical References
  • Glucocorticoids
  • Hypoglycemic Agents
  • Insulin
  • Prednisolone
  • Adult
  • Diabetes Mellitus, Type 1 (complications, drug therapy)
  • Female
  • Glucocorticoids (administration & dosage)
  • Humans
  • Hypoglycemic Agents (administration & dosage)
  • Insulin (administration & dosage, analogs & derivatives)
  • Lower Extremity (pathology)
  • Necrobiosis Lipoidica (drug therapy, etiology, pathology)
  • Prednisolone (administration & dosage)
  • Skin (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: